Tweets

You blocked @chamath

Are you sure you want to view these Tweets? Viewing Tweets won't unblock @chamath

  1. Pinned Tweet

    Here’s my 2020 Annual letter… - Returns - Year in review - Inequality, climate change, BLM - Market color - Secrets hiding in plain sight - Comparison to S&P500 and

    Undo
  2. Jan 29
    Undo
  3. Jan 27

    5/ More details attached – which also includes a summary of EM21’s Year 1 performance as well as our standard term sheet. Send all applications to [email protected] by Feb 11.

    Show this thread
    Undo
  4. Jan 27

    4/ In addition to U.S. equities, 2022 applicants may submit actively managed crypto strategies. Why crypto? With the emergence of Web3, we don’t want to miss exposure to one of the fastest growing asset classes. We’re open to all liquid crypto strategies focused on trading.

    Show this thread
    Undo
  5. Jan 27

    3/ We’re excited to invite folks to apply for the EM Class of 2022. As an EM, you have access to three key benefits: (1) capital commitment of 3 years; (2) the platform/infrastructure required to trade; (3) ability to own your track record outright.

    Show this thread
    Undo
  6. Jan 27

    2/ We hired 11 managers, initially staking them with $4M each. They managed their own books, while also working on investments and other projects. After reviewing year-end performance, we have allocated additional capital for year 2 of the cohort.

    Show this thread
    Undo
  7. Jan 27

    1/ Last year, we launched Emerging Managers, a program designed for investment professionals looking to accelerate their careers without the typical years of waiting it takes to be allocated your own portfolio at traditional funds.

    Show this thread
    Undo
  8. Jan 26

    6/ We’re excited our biotech SPAC platform is able to partner with another company that is rethinking how we approach some of America’s most pressing healthcare issues, in this case our cognitive health. Read more in our investment thesis. Disclaimer:

    Show this thread
    Undo
  9. Jan 26

    5/ Importantly, while Akili's patented technology is used to treat ADHD today, they have the opportunity to eventually treat a whole host of other cognitive issues like major depressive disorder, multiple sclerosis, and autism spectrum disorder.

    Show this thread
    Undo
  10. Jan 26

    4/ Akili's lead product – EndeavorRx – has been clinically validated and shown similar outcomes to prescription drugs. This breakthrough therapy is powered by technology that directly targets cognitive function vs. current treatments which focus on symptoms and coping strategies.

    Show this thread
    Undo
  11. Jan 26

    3/ Their technology targets the fronto-parietal attention control networks of the brain to improve attention function (e.g., focus, multitasking).

    Show this thread
    Undo
  12. Jan 26

    2/ is creating a new class of medicine. Their first product is a first-of-its-kind FDA-cleared prescription video game to treat pediatric ADHD in 8-12 year-olds.

    Show this thread
    Undo
  13. Jan 26

    1/ As a parent, I often wonder whether there is a way for technology to be part of the solution to our country’s growing concerns around mental health. And then we met and his team at .

    Show this thread
    Undo
  14. Jan 18

    4/ Our investment thesis in ProKidney attached. Disclaimer:

    Show this thread
    Undo
  15. Jan 18

    3/ By taking ProKidney public, they will have the capital to continue Phase 3 clinical trials which have already commenced this month. We are excited to work with a company that has the opportunity to change how millions of people worldwide cope with this terrible disease

    Show this thread
    Undo
  16. Jan 18

    2/ Today we partnered with ProKidney, which is changing how we treat CKD. Their clinical data shows its treatment can not only significantly slow the onset of CKD compared to existing therapies, but even REVERSE the loss of kidney function, a first for CKD patients

    Show this thread
    Undo
  17. Jan 18

    1/ Chronic kidney disease (CKD) is one of the most prevalent medical conditions, affecting more than 1 in 7 U.S. adults (as well as my late father). We spend up to $500B/yr to treat CKD with drugs and dialysis, which may incrementally slow down the disease but not reverse it

    Show this thread
    Undo
  18. Undo
  19. Jan 17

    Important issues deserve nuanced discussions. Some clarifying comments:

    Undo
  20. Jan 15

    As I said on - we are now peak Big Tech. This work environment sounds like a nightmare.

    This Tweet is unavailable.
    Undo
  21. Jan 15
    Undo

Loading seems to be taking a while.

Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.

    You may also like

    ·